Pancreatic Cancer Treatment Guidelines

Introduction to Pancreatic Cancer Treatment

• The European Society for Medical Oncology (ESMO) recommends surgical resection followed by adjuvant chemotherapy for pancreatic cancer treatment, with consideration of chemoradiation in select cases 1, 2

First-Line Treatment

• For patients with good performance status (ECOG 0-1) and bilirubin <1.5× upper limit of normal, ESMO recommends FOLFIRINOX or gemcitabine plus nab-paclitaxel as treatment options, with FOLFIRINOX improving median overall survival to 11.1 months compared to 6.8 months with gemcitabine alone 3, 1, 2
• For patients with moderate performance status (ECOG 2) and/or elevated bilirubin, ESMO recommends gemcitabine monotherapy 3, 1, 2
• For patients with poor performance status (ECOG 3-4), ESMO recommends symptomatic treatment only 3, 1, 2

Second-Line Treatment

• The European Society for Medical Oncology (ESMO) recommends 5-FU/oxaliplatin for patients who have progressed on first-line treatment 1

Palliative Care

• Healthcare providers should consider palliative care options for symptom management, including pain control with opioids, endoscopic stenting for jaundice, and celiac plexus blockade for pain, as per the European Society for Medical Oncology (ESMO) guidelines 1, 2

Unproven Therapies

• ESMO guidelines recommend participation in clinical trials of promising new therapies rather than unproven alternatives, and do not include ivermectin, fenbendazole, or tirzepatide as part of any established treatment guidelines for pancreatic cancer due to lack of clinical evidence 3, 1, 2, 4
• Self-medication with unproven therapies like ivermectin may lead to toxicity, delay in receiving established effective treatments, and false hope and financial burden 1, 2

Healthcare Provider Recommendations

• Healthcare providers should adhere to established treatment guidelines for pancreatic cancer, discourage the use of unproven therapies, and direct patients toward evidence-based interventions with proven survival benefits, as per the European Society for Medical Oncology (ESMO) guidelines 3, 1, 2
• Gemcitabine-based therapy is a recommended treatment option, and chemoradiation should only be performed within clinical trials 4